Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
American Journal of Physiology. Cell Physiology|May 6, 2005
Do rat cardiac myocytes release ATP on contraction?Stefanie Gödecke, Thomas Stumpe, Hilmar Schiller, et al.
Pharmaceutical Biology|July 13, 2013
The potential of Hypoxis hemerocallidea for herb-drug interactionPius S Fasinu, Heike Gutmann, Hilmar Schiller, et al.
Drug Metabolism and Personalized Therapy|November 28, 2017
Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) - a comparison with the chemical inhibition methodKen-Ichi Umehara, Felix Huth, Helen Gu, et al.
Drug Metabolism and Personalized Therapy|October 9, 2016
Improvement of the chemical inhibition phenotyping assay by cross-reactivity correctionNicholas M Njuguna, Ken-Ichi Umehara, Felix Huth, et al.
Drug Metabolism and Personalized Therapy|May 31, 2019
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissionsKenichi Umehara, Felix Huth, Yi Jin, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 5, 2012
The potential of Sutherlandia frutescens for herb-drug interactionPius S Fasinu, Heike Gutmann, Hilmar Schiller, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 13, 2019
Examining P-gp efflux kinetics guided by the BDDCS - Rational selection of in vitro assay designs and mathematical modelsJulia Riede, Ken-Ichi Umehara, Patrick Schweigler, et al.
Clinical Pharmacokinetics|January 20, 2024
Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast CancerYan Ji, Hilmar Schiller, Shu Yang, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 5, 2022
Novel Bruton's tyrosine kinase inhibitor remibrutinib: Assessment of drug-drug interaction potential as a perpetrator of cytochrome P450 enzymes and drug transporters and the impact of covalent binding on possible drug interactionsHilmar Schiller, Felix Huth, Carole Schuhler, et al.
Clinical and Translational Science|August 25, 2021
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modelingFelix Huth, Hilmar Schiller, Yi Jin, et al.
Pageof 3